Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials

The Lancet Oncology

Volumn 11, Issue 7, 2010, Pages 627-636

  Sipahi, I ^a   Debanne, S M ^b   Rowland, D Y ^b   Simon, D I ^a   Fang, J C ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LUNG CANCER; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 77954030665     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70106-6     Document Type: Article

References (48)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
3. Diabetes Care 2009, 32(suppl 1):S13-S61. Standards of medical care in diabetes-2009.
4. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
5. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
6. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006, 354:1685-1697.
7. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174-1183.
8. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
9. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225-1237.
10. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
11. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008, 372:1394-1402.
12. Dickstein K, Kjekshus J Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360:752-760.
13. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
15. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
16. Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008, 51:393-398.
17. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
18. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
19. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
20. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007, 369:1431-1439.
21. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005, 36:1218-1226.
22. Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008, 372:1385-1393.
23. Suzuki H, Kanno Y Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005, 28:307-314.
24. COZAAR: highlights of prescribing information Merck & Co, (accessed May 26, 2010). http://www.merck.com/product/usa/pi_circulars/c/cozaar/cozaar_pi.pdf.
25. ATACAND: highlights of prescribing information AstraZeneca, (accessed May 26, 2010). http://www1.astrazeneca-us.com/pi/Atacand.pdf.
26. MICARDIS: material safety data sheet Boehringer Ingelheim, (accessed May 26, 2010). http://bi-msds.e3solutionsinc.com/Micardis%20tabletsR2.pdf.
27. Deshayes F, Nahmias C Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metab 2005, 16:293-299.
28. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74-80.
29. Micardis (Telmisartan) Cardiovascular and Renal Drugs Advisory Committee briefing document (accessed April 13, 2010). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM173529.pdf.
30. Marciniak TA Clinical Review, Supplemental NDA Submission, NDA 20-386, Cozaar Tablets, Merck & Co (accessed April 13, 2010). http://www.fda.gov/ohrms/dockets/ac/03/briefing/3920B1_02_A-FDA-Cozaar%20Clinical%20Review.htm.
31. Khin Maung U Clinical Review, N20-838/SE1-022, Atacand (Candesartan cilexetil) tablets (accessed April 13, 2010). http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4092B1_01_03-FDA-Clinical-Review-S022-02-Pages_100-199.pdf.
32. Khin Maung U Clinical Review, N20-838/SE1-022, Atacand (Candesartan cilexetil) tablets (accessed April 13, 2010). http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4092B1_01_05-FDA-Clinical-Review-S024-03-Pages_200-241.pdf.
33. Application Number NDA 21-283/S011 Combined Medical and Statistical Review Center For Drug Evaluation and Research Approval Package For, (accessed April 13, 2010). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021283_S011_DIOVAN_MEDR%20&%20STATR.pdf.
34. Diovan (Valsartan) Congestive Heart Failure Advisory Comittee Briefing Document (accessed April 13, 2010). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3793b1_01_NOVARTIS.pdf.
35. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
36. Dahlof B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE study group. Am J Hypertens 1997, 10:705-713.
37. Begg CB, Mazumdar M Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
38. Wessa P Kendall tau Rank Correlation (v1.0.10) in Free Statistics Software (v1.1.23-r4), Office for Research Development and Education (accessed April 13, 2010). http://www.wessa.net/rwasp_kendall.wasp.
39. United States Cancer Statistics: 1999-2006 Incidence and Mortality Web-based Report 2010, US Cancer Statistics Working Group, US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta, (accessed April 13, 2010). http://www.cdc.gov/uscs.
40. Altman DG, Deeks JJ Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol 2002, 2:3.
41. Smeeth L, Haines A, Ebrahim S Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ 1999, 318:1548-1551.
42. Cohn JN, Tognoni G A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
43. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
44. Nissen SE, Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
45. Institute NC Surveillance Epidemiology and End Results (SEER) Cancer Statistics Review 1975-2006 (accessed April 13, 2010). http://seer.cancer.gov/csr/1975_2006/results_merged/topic_lifetime_risk.pdf.
46. Coleman CI, Baker WL, Kluger J, White CM Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008, 26:622-629.
47. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 2009, 8:1676-1683.
48. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 2003, 17:2061-2067.